Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HST Global, Inc. (HSTC)
Hampton, VA, US
HST Global, Inc. operates as a biotechnology firm dedicated to integrated health and wellness. The company establishes and acquires a global network of specialized wellness centers, which offer homeopathic and alternative treatments primarily for patients suffering from advanced-stage cancers. Furthermore, HST Global focuses on the development of homeopathic and alternative therapeutic candidates that are either currently undergoing or have successfully completed clinical trials. These potential treatments are designed to address late-stage cancers as well as various other critical, life-threatening conditions. The company's corporate headquarters are situated in Hampton, Virginia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -29.29% | +40.00% | -30.00% | -29.29% | -15.66% | +289.13% | +797.44% | +1,066.69% | -97.01% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-27.1% Q2'26: +100.0% (vs Q2'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-188.4% Q2'26: -16.5% (vs Q2'25)
-
EBIT margin Biotechnology: +0.0%-154.6% Q2'26: +21.1% (vs Q2'25)
-
ROIC Biotechnology: -16.1%-6.1% ★ Q2'26: +1.3% (vs Q2'25)
-
Share dilution Biotechnology: -3.4%+220.5% Q2'26: +144.8% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.52× Q2'26: 2.78× (vs Q2'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 75-2296301 | 6.36M | 42.34% | 6.36M | — | 6.36M | — | IV, PN | Texas | 1998-02-06 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-13 | Field Michael L | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 19,791,060 | — | ↗ |
| 2024-04-14 | Murphy Jason | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 19,791,060 | — | ↗ |
| 2010-12-31 | Howell Ronald R. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-12-31 | Howell Ronald R. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-12-31 | Howell Ronald R. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-05-09 | Tate Wesley D. | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-05-09 | Howell Ronald R. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-06-19 | PNC LABS INC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 19,433,040 | — | ↗ |
| 2007-06-17 | LEW ALAN | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 134,079 | — | ↗ |
| 2006-06-21 | TSUN CHUN KA | Director / Officer / 10% Owner | A-Award | D | NT Holding Corp. Common Stock | 10,338,220 | 0.00 | — | 0 | — | ↗ |
| 2006-06-21 | KING CHEN TSZ | 10% Owner | A-Award | A | NT Holding Corp. Common Stock | 10,338,220 | 0.00 | — | 10,313,060 | — | ↗ |
| 2005-11-01 | TSUN CHUN KA | Director / Officer / 10% Owner | — | I | NT Holding Corp. Common Stock | 0 | 0.00 | — | 10,338,220 | — | ↗ |
| 2005-11-01 | TANG LI SZE | 10% Owner | — | I | NT Holding Corp. Common Stock | 0 | 0.00 | — | 632,960 | — | ↗ |
| 2005-11-01 | KING CHEN TSZ | 10% Owner | — | I | NT Holding Corp. Common Stock | 0 | 0.00 | — | 8,974,840 | — | ↗ |
| 2004-10-15 | TODD ANDRE E | Officer | C-Conversion | A | warrants | 12,500 | 0.40 | 5.0K | 25,000 | — | ↗ |
| 2004-10-15 | LEW ALAN | Director / Officer / 10% Owner | C-Conversion | A | Warrants | 12,500 | 0.60 | 7.5K | 25,000 | — | ↗ |
| 2003-11-15 | ETRA AARON | Director | C-Conversion | A | warrants | 12,500 | 0.40 | 5.0K | 25,000 | — | ↗ |
| 2003-09-02 | TODD ANDRE E | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-09-02 | ETRA AARON | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-09-02 | COMMUNICATIONS HOLDING CORP | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
| 2003-07-11 | LEW ALAN | Director / Officer / 10% Owner | — | D | Common Stock at par value $.0001 | 0 | 0.00 | — | 4,200,040 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Fortkort | Vice President, Interim Chief Executive Officer & Director | — | male |
| Mike Field | President, Interim Chief Financial Officer & Director | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HSTC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
